Nuveen Asset Management LLC Decreases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Nuveen Asset Management LLC cut its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 28.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 260,697 shares of the company’s stock after selling 105,170 shares during the period. Nuveen Asset Management LLC owned 0.26% of Intellia Therapeutics worth $3,040,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of NTLA. ARK Investment Management LLC boosted its stake in Intellia Therapeutics by 2.3% during the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock valued at $146,174,000 after buying an additional 280,946 shares during the period. Vanguard Group Inc. boosted its stake in Intellia Therapeutics by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock valued at $118,816,000 after buying an additional 562,249 shares during the period. Regeneron Pharmaceuticals Inc. bought a new stake in Intellia Therapeutics during the fourth quarter valued at $43,177,000. Geode Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock worth $27,865,000 after acquiring an additional 45,930 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Intellia Therapeutics by 36.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company’s stock worth $23,042,000 after acquiring an additional 528,962 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NTLA has been the subject of a number of research analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $68.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 9th. The Goldman Sachs Group reiterated a “sell” rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Wolfe Research upgraded shares of Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price on the stock in a research report on Monday, April 21st. Citigroup decreased their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. Finally, Guggenheim decreased their target price on shares of Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, May 12th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.75.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $7.16 on Tuesday. The stock has a market cap of $741.65 million, a PE ratio of -1.32 and a beta of 2.33. The business has a fifty day moving average of $7.91 and a two-hundred day moving average of $10.18. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. The business’s quarterly revenue was down 42.6% compared to the same quarter last year. During the same quarter last year, the business posted ($1.12) earnings per share. Analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.